Poster presentations

**Conclusion** We propose that with good interagency and MDT working, an efficient and effective ART delivery service is feasible, with patient and hospital benefits. Collaborative approaches between the delivery service and HIV MDT should be established and regularly evaluated with patient input. Identifying a key contact person for the delivery service is important to ensure continuity of communication, together with a local contractual service level agreement to ensure clear terms of reference and accountability. Results of a qualitative patient survey evaluating the delivery service are imminent.

**Background** In 2011, 1.3 million sexual health screens (SHS) were conducted in genitourinary medicine clinics across the UK, a doubling of workload in the last 8 years. One approach UK clinicians have adopted in managing this increase is for minimally trained non-medical staff (health care support workers (HCSWs)) to deliver protocol driven asymptomatic screening to low risk patients. There is limited research regarding patient confidence with the service offered by HCSWs and re-attendance rates could be an indicator of patient dissatisfaction.

**Aim** To assess whether patients who have asymptomatic screening with HCSWs were more likely to return for subsequent assessment by a clinician following discharge.

**Method** A case controlled study of 300 asymptomatic patients attending for sexual health screening between October 2011 and April 2012. There were 2 arms with equal patient numbers, the HCSW led clinic and the clinician led clinic. Data collection and analysis for both groups included patient demographics, diagnoses, treatment, test results and time to next new diagnosis.

**Results** No significant difference was found between the patient demographics of the two groups. The rates of Chlamydia infection between the HCSW and the clinician groups were 8% and 7.5% respectively. Within the clinician group 4 cases of syphilis, 1 new diagnosis of HIV and case of Hepatitis C were also diagnosed. The HCSW clinic had 19 (12.7%) patients re-attended for further screening within 11 months compared to 16 (10.7%) patients who saw a clinician, showing no significant difference between the two groups [p = 0.124 Fishers exact test]. Only 1 patient from each group re-attended within 6 weeks for further screening due to the development of symptoms.

**Conclusion** This study highlights low patient re-attendance rates within the HCSW group. This is an indirect marker of patient satisfaction and demonstrates patients are reassured with the service they offer.

**Background** The BRAVO trial is an ongoing study designed to determine whether bi-monthly home-screening and treatment for asymptomatic bacterial vaginosis (BV) reduces risk of urogenital chlamydia and gonorrhoea infections in young women. Return rate of self-collected swabs is a critical element of home testing interventions. We conducted this preliminary analysis to determine the swab return rate and to assess its association with age, race, and recruitment setting.

**Methods** Participants, recruited from 10 clinics in 5 cities, were asked to mail self-collected vaginal swabs to the research team every 2 months for one year. For each evaluable participant, we determined the number of kits returned (of 6 total) and compared the proportion of women that returned all 6 kits according to age, race, and recruitment setting.

**Results** Data were available for 756 participants who were primarily non-Hispanic Blacks (76%), with median age 21 (range: 17–25 years), and mostly recruited from STD clinics (82%). Nearly all women (89%) returned at least one swab; 59% returned all 6 kits; 14% returned 5; 16% returned 1–4, and 11% returned none. Complete swab return rate (all 6) was greater among women aged 23–25 than those aged 17–22 (67% vs. 56%, p < 0.01) and varied among the 5 recruitment cities (range 42%–66%, p = 0.02). Return rates were not significantly associated with race and Hispanic ethnicity, or with recruitment from STD clinics vs. other settings (58% vs. 66%, p = 0.10).

**Conclusions** The majority of study participants collected and submitted all six home-screening kits, and 78% completed at least five. Adolescent women aged 22 and younger had a lower return rate than women aged 23–25, although the complete return rate was still over 50%. Therefore, frequent home-screening for BV and STIs is feasible in clinical trial settings and could likely be implemented as part of clinical care and STD prevention programmes.